2643974-98-3
Chemical Structure
Trabikibart
Synonym(s): CSL311
- CAS No.: 2643974-98-3
- Formula:N/A
- Molecular Weight:(144.66 kDa)
SMILES: [Trabikibart]
Biological Activity: Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Trabikibart | 99.17% | Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wang H, et al. Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models. Cell Death Dis. 2022;13(2):137. Published 2022 Feb 10. [Content Brief]
- [2]. Kan WL, et al. The β Common Cytokine Receptor Family Reveals New Functional Paradigms From Structural Complexities. Immunol Rev. 2025;329(1):e13430. [Content Brief]
- [3]. Yip KH, et al. Anti‐β c mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model. Allergy. 2020 Feb 1;75(2).
- [4]. Wang H, et al. Dual inhibition of airway inflammation and fibrosis by common β cytokine receptor blockade. J Allergy Clin Immunol. 2024;153(3):672-683.e6. [Content Brief]
Keywords
